> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Extends Astellas Fezolinetant PDUFA Action Date
- URL: https://www.fdaweb.com/fda-extends-astellas-fezolinetant-pdufa-action-date/
- Published: 2023-02-21T12:00:00.000Z
- Updated: 2026-09-14T18:16:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153817

FDA has extended to 5/22 the PDUFA priority review action date for Astellas Pharma’s fezolinetant, an investigational drug to treat moderate to severe vasomotor symptoms due to menopause. The company [says](https://www.astellas.com/en/news/27281?ref=fdaweb.com) the agency said it needed more time to complete its review of the Astellas NDA.